ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Intesity Therapeutics Inc

Intesity Therapeutics Inc (INTS)

2,325
-0,0149
(-0,64%)
Beim Schlusskurs: 13 März 9:00PM
2,15
-0,175
( -7,53% )
Nach Börsenschluss: 10:08PM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
2,15
Gebot
2,15
Fragen
2,26
Volumen
14.121
2,23 Tagesbereich 2,39
1,50 52-Wochen-Bereich 5,78
Marktkapitalisierung
Handelsende
2,3399
Handelsbeginn
2,38
Letzter Handelszeitpunkt
22:08:18
Finanzvolumen
US$ 32.513
VWAP
2,3025
Durchschnittliches Volumen (3 Mio.)
32.968
Ausgegebene Aktien
13.867.697
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-2,71
Gewinn pro Aktie (EPS)
-0,86
Erlöse
-
Nettogewinn
-11,86M

Über Intesity Therapeutics Inc

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive... Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The Company's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. It also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725). Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Intesity Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker INTS. The last closing price for Intesity Therapeutics was US$2,34. Over the last year, Intesity Therapeutics shares have traded in a share price range of US$ 1,50 to US$ 5,78.

Intesity Therapeutics currently has 13.867.697 shares in issue. The market capitalisation of Intesity Therapeutics is US$32,45 million. Intesity Therapeutics has a price to earnings ratio (PE ratio) of -2.71.

INTS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.24-10.04184100422.392.432.15172672.28353986CS
40.020.938967136152.132.432184712.21707644CS
120.14937.462388164142.00073.16631.5329682.22331627CS
26-2.0768-49.13409671624.22684.251.5268102.51711743CS
52-2.2-50.57471264374.355.781.5210923.32345514CS
156-3.8-63.86554621855.9511.441.51161266.34258706CS
260-3.8-63.86554621855.9511.441.51161266.34258706CS

INTS - Frequently Asked Questions (FAQ)

What is the current Intesity Therapeutics share price?
The current share price of Intesity Therapeutics is US$ 2,15
How many Intesity Therapeutics shares are in issue?
Intesity Therapeutics has 13.867.697 shares in issue
What is the market cap of Intesity Therapeutics?
The market capitalisation of Intesity Therapeutics is USD 32,45M
What is the 1 year trading range for Intesity Therapeutics share price?
Intesity Therapeutics has traded in the range of US$ 1,50 to US$ 5,78 during the past year
What is the PE ratio of Intesity Therapeutics?
The price to earnings ratio of Intesity Therapeutics is -2,71
What is the reporting currency for Intesity Therapeutics?
Intesity Therapeutics reports financial results in USD
What is the latest annual profit for Intesity Therapeutics?
The latest annual profit of Intesity Therapeutics is USD -11,86M
What is the registered address of Intesity Therapeutics?
The registered address for Intesity Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
Which industry sector does Intesity Therapeutics operate in?
Intesity Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
RDUSRadius Recycling Inc
US$ 28,4982
(108,63%)
10,55k
MRMMEDIROM Healthcare Technologies Inc
US$ 1,27
(104,84%)
2,7M
AAOIApplied Optoelectronics Inc
US$ 28,76
(81,22%)
1,85M
PRPLPurple Innovation Inc
US$ 0,8188
(23,41%)
3,29M
TNFATNF Pharmaceuticals Inc
US$ 0,415
(19,60%)
87,48k
MKDWMKDWELL Tech Inc
US$ 0,3214
(-21,15%)
4,12k
LGCBLinkage Global Inc
US$ 0,1839
(-19,48%)
5,64M
NAYANAYA Biosciences Inc
US$ 0,259
(-19,34%)
80,87k
ABLVAble View Global Inc
US$ 0,8105
(-18,95%)
831
QVCGBQVC Group Inc
US$ 4,53
(-14,53%)
2,55k
ICONIcon Energy Corporation
US$ 0,129
(-5,15%)
9,03M
LGCBLinkage Global Inc
US$ 0,1839
(-19,48%)
5,64M
ADTXAditxt Inc
US$ 0,03165
(-5,24%)
4,37M
DGLYDigital Ally Inc
US$ 0,0814
(2,52%)
4,14M
HEPAHepion Pharmaceuticals Inc
US$ 0,037
(-2,12%)
3,46M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen